Form 4: Zenas BioPharma R&D Head Receives Stock Option Grant
Insider Compensation Disclosure
Lisa von Moltke, Head of R&D and CMO of Zenas BioPharma, was granted 150,000 stock options with an exercise price of $18.71.
Summary
- Lisa von Moltke, Head of Research and Development and Chief Medical Officer, received a grant of 150,000 stock options.
- The options have an exercise price of $18.71 per share.
- The grant date for the transaction is June 15, 2026.
- The options are set to expire on June 15, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential future dilution of existing shareholders upon the exercise of these options.
Risks
- Market volatility affecting the value of the granted options.
- Dependence on continued service for the vesting of the equity grant.
Future Outlook
The options vest over a four-year period, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following 36 months, contingent upon continued service.
Management Comments
- The reporting person serves as the Head of Research and Development and Chief Medical Officer.
Industry Context
StockSavvy.ai notes that equity grants for key R&D and medical leadership are standard practice in the biotechnology sector to retain talent during critical clinical development phases.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard industry practices for executive equity compensation in mid-cap biotech firms.
Stakeholder Impact
- Shareholders may experience minor dilution if options are exercised in the future.
Next Steps
- Vesting of 25% of options on June 15, 2027.
- Continued monthly vesting of remaining options through June 2030.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Transaction date of the stock option grant. |
| 06/15/2027 | Initial vesting date for 25% of the granted options. |
| 06/15/2036 | Expiration date of the stock options. |
Keywords
Zenas BioPharma, ZBIO, Form 4, Insider Trading, Stock Options, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.